Few areas of women's health have been shaped as decisively by a single study, or as damaged by its misinterpretation, as menopause hormone therapy. The Women's Health Initiative (WHI), whose initial results were released in 2002, led to a rapid decline in prescriptions and a generation of clinicians trained to view hormone therapy with more caution than the evidence supported. Two decades of reanalysis have produced a more nuanced picture, and the current guidelines look quite different from the headlines many people still remember.
The North American Menopause Society (NAMS), ACOG, and the Endocrine Society have converged on a broadly similar position, one that most menopause-trained clinicians now share. It is worth understanding what changed and what did not.
What WHI actually showed
WHI enrolled more than 27,000 postmenopausal people in two arms, one testing estrogen plus progestin in participants with an intact uterus, one testing estrogen alone in those who had had a hysterectomy. The average age at enrollment was 63, well past the typical menopause transition.
The combined-therapy arm was stopped early in 2002 after finding a small increase in breast cancer and cardiovascular events. The message the public received was that hormone therapy causes cancer and heart disease. What subsequent reanalyses showed was more specific:
- Risk profile depends heavily on age at initiation and time since menopause
- The estrogen-only arm showed different, generally more favorable results
- Absolute risk increases were small even in the higher-risk subgroups
- Benefits, including reduced fractures and, for some, reduced all-cause mortality, were also underreported at the time
The timing hypothesis
What has emerged is the timing hypothesis, or the window of opportunity concept. Hormone therapy started within roughly ten years of menopause onset, or before age 60, appears to have a substantially different risk-benefit profile than therapy started a decade or more later. In the younger group, cardiovascular effects appear neutral to potentially beneficial, and benefits for symptoms, bone, and quality of life are more likely to outweigh risks.
This does not mean hormone therapy is risk-free. It means the risk conversation belongs to individuals, not to broad averages that lumped a 55-year-old with vasomotor symptoms together with a 70-year-old without.
What the current guidelines say
The 2022 NAMS position statement, updated with additional evidence since, offers these broad principles:
- Hormone therapy is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause
- For healthy people under 60 or within 10 years of menopause onset, benefits generally outweigh risks
- There is no arbitrary duration limit; ongoing use is a shared decision reviewed periodically
- Transdermal estrogen carries lower thromboembolism risk than oral, particularly relevant for people with cardiovascular risk factors
- Micronized progesterone is often preferred over older synthetic progestins for uterine protection in people with an intact uterus
- Local vaginal estrogen is separate from systemic therapy and is safe for most people, with minimal systemic absorption
The most consequential shift has been from asking whether hormone therapy is safe in general to asking whether it is appropriate for a specific person, at a specific age, with a specific symptom burden and risk profile.
Who is not a candidate
Systemic hormone therapy is generally not appropriate for people with a history of hormone-sensitive cancer, unexplained vaginal bleeding, active liver disease, a recent stroke or heart attack, or a history of venous thromboembolism, though some of these are relative rather than absolute contraindications, and local vaginal estrogen may still be an option after specialist consultation.
What to ask
Useful questions include: Am I in the timing window? What is my baseline breast, cardiovascular, and clot risk? Would transdermal be preferable to oral for me? What formulation of progestogen makes sense if I have a uterus? How will we monitor and reassess?
If your clinician is broadly uncomfortable prescribing hormone therapy, that is a training gap, not a red flag about you. NAMS maintains a directory of certified menopause practitioners.
The bottom line
Hormone therapy is neither a cure-all nor the danger it was once portrayed as. For many healthy people in the years around menopause, it is the most effective treatment we have for symptoms that can dominate a decade of life. The decision is individual, and the conversation should reflect the current evidence, not the 2002 headlines.